Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U

    Vidit Sharma

    Assistant Professor of Urology
    Mayo Clinic, United States

    Vidit Sharma is an Assistant Professor of Urology with a surgical focus on kidney cancer. His research focus is in health services research and artificial intelligence broadly across urologic oncology. 

    Training:
    Undergraduate degree: Northwestern University (Economics)
    Medical School: Northwestern University
    Urology Residency: Mayo Clinic
    SUO Fellowship: UCLA + Mayo Clinic Hybrid SUO fellowship
    - Masters of Science in Health Services research at UCLA

    Since fellowship, he was hired as an assistant professor at Mayo Clinic in 2022 and was appointed as the Associate Program Director of the Urologic Oncology Fellowship starting in July of 2024. He mentors oncology fellows through their research and spends at least 2 months with each fellow on his service through the mentorship model structure of our training program.

    Dr. Sharma has maintained an active research program, publishing over 130 articles indexed on Medline. He has used cost-effectiveness analyses that use Markov modeling to inform therapeutic algorithms in prostate, bladder, and kidney cancer. He is also the Principal Investigator of Mayo Clinic’s prospective Nephrectomy Registry and has published studies related to RCC risk stratification and surgical outcomes.

    He has obtained internal and external grant funding for artificial intelligence algorithms to: 1) automatically identify kidney tumors on CT scans, and 2) improve outcomes for RCC patients with venous tumor thrombus.  Specifically, he has received the Research Scholar Award ($80,000) from the American Urologic Associations Urology Care Foundation to improve outcomes with RCC and venous tumor thrombus. He has also obtained over $300,000 in internal funding to improve bladder cancer staging. He is the co-PI on a current Department of Defense grant ($277,000) that aims to differentiate benign from malignant renal tumors.

    Presentation(s):